HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Platelet-induced tolerance in the production of heteroantisera to human leukemia-associated antigens.

Abstract
A method is described for raising antisera to human leukemia cells of an individual patient in mice rendered tolerant with cyclophosphamide to platelets obtained from the same patient. The resulting antisera are able to distinguish serologically between leukemic blast cells and remission cells of patients with acute leukemia and may be recognizing leukemia-associated antigens. The antisera are similar in activity to antisera raised following tolerance-induction with remission leukocytes, but larger volumes of anti-leukemia antiserum can be raised using the more easily obtainable platelets. This technique provides further evidence that human platelets share many of the antigens present on human leukocytes.
AuthorsM A Baker, R N Taub
JournalJournal of immunological methods (J Immunol Methods) Vol. 10 Issue 2-3 Pg. 171-5 (Mar 1976) ISSN: 0022-1759 [Print] Netherlands
PMID1064673 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antigens, Neoplasm
  • Immune Sera
  • Cyclophosphamide
Topics
  • Acute Disease
  • Antigens, Neoplasm (administration & dosage)
  • Blood Platelets (immunology)
  • Cyclophosphamide (administration & dosage)
  • Humans
  • Immune Sera (isolation & purification)
  • Immune Tolerance
  • Injections, Intraperitoneal
  • Leukemia (immunology)
  • Leukemia, Lymphoid (immunology)
  • Leukemia, Myeloid, Acute (immunology)
  • Remission, Spontaneous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: